ASCO GU 2024: Key Studies
An Expert’s Guide to Key Studies at the 2024 ASCO Genitourinary Cancers Symposium

Released: January 24, 2024

Terence Friedlander
Terence Friedlander, MD
Rana R. McKay
Rana R. McKay, MD

Activity

Progress
1
Course Completed

During the ASCO Genitourinary Cancers Symposium being held January 25-27, 2024, up-to-date results from many clinical trials in genitourinary malignancies will be reported. Here are the key studies to watch for, as chosen by Terence Friedlander, MD, and Rana R. McKay, MD. These and other clinically relevant data will be covered online as part of CCO’s Independent Conference Coverage of ASCO GU 2024.

Top Studies of Interest

Prostate Cancer

  • The phase III CONTACT-2 trial reports positive data for the coprimary endpoint of radiographic progression-free survival with the combination of cabozantinib plus atezolizumab vs novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and visceral metastases after progression on a novel hormonal therapy.
  • The phase II BRCAAway trial comparing the PARP inhibitor olaparib vs abiraterone vs the combination of olaparib and abiraterone will help answer questions about when and how to best use olaparib for patients with metastatic castration-resistant prostate cancer and BRCA or ATM mutations.

Bladder Cancer

  • Late-breaking data on a subgroup analysis from the phase III EV-302 trial of the recently approved combination of enfortumab vedotin plus pembrolizumab vs chemotherapy as first-line therapy for locally advanced or metastatic urothelial carcinoma.
  • Late-breaking report on adjuvant pembrolizumab for muscle-invasive or locally advanced urothelial carcinoma from the phase III AMBASSADOR Alliance A031501 trial.
  • The primary outcome of objective response rate from the single-arm phase II PemCab trial of cabozantinib plus pembrolizumab as first-line therapy for patients with cisplatin-ineligible advanced urothelial carcinoma will be presented.
  • Retrospective study analyzing optimal sequencing of erdafitinib and enfortumab vedotin in patients with FGFR2/3-altered advanced urothelial cancer.

Renal Cancer

  • Late-breaking data on overall survival with adjuvant pembrolizumab vs placebo in clear cell renal carcinoma (RCC) from the phase III KEYNOTE-564 trial are eagerly anticipated and will provide insight into the value of adjuvant therapy in RCC.

Additional Studies of Interest

  • Late-breaking, longer-term data from the GETUG-AFU 18 trial comparing 2 different doses of radiation in patients with prostate cancer receiving prolonged androgen deprivation therapy. 
  • A report on the safety and efficacy data of the novel anti-DLL3, trispecific T-cell engager HPN328 in neuroendocrine prostate cancer and small-cell bladder cancer. 
  • Efficacy and safety of the oral MetAP2 inhibitor APL-1202 plus the anti–PD-1 antibody tislelizumab in patients with muscle-invasive bladder cancer from the phase II ANTICIPATE trial.
  • CheckMate 914: phase III trial comparing adjuvant nivolumab vs placebo in localized RCC at high risk of relapse post nephrectomy, part B results.
  • Updated long-term follow-up of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib as first-line therapy for advanced RCC continues to show benefit of the combination of nivolumab plus cabozantinib.
  • 6-year survival, response, and safety data from the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab vs sunitinib in advanced RCC demonstrate continued benefit with the combination of nivolumab plus ipilimumab.
  • Late-breaking safety, efficacy, and pharmacokinetic results from the phase III CheckMate 67T trial of SC nivolumab vs IV nivolumab in patients with advanced or metastatic clear cell RCC after previous therapy.

Remember to Check the CCO Website After ASCO GU 2024!
These are just a few of the exciting abstracts selected by our expert faculty from ASCO GU 2024. Downloadable slidesets summarizing the data from these studies will be available on our website, along with a comprehensive analysis by our expert faculty members, who will explore the implications of the data in an CME/CNE/ACPE/AAPA-certified text-based module.

Poll

1.

Which of the following presentations are you most looking forward to seeing from ASCO GU 2024?

Submit